NICE has rejected Amgen’s Kyprolis in second line multiple myeloma treatment in first draft guidance, citing uncertainties over long-term survival benefits. The cost-effectiveness body is ...
Combined with Revlimid and dexamethasone, Kyprolis extended progression-free survival (PFS) by 8.7 months (from 17.6 months to 26.3 months), compared to Revlimid and dexamethasone alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback